The Cognitive and Cerebral Blood Flow Effects of Resveratrol - Full Text View

Purpose

Research shows that resveratrol is able to induce vasodilation (and therefore blood flow) by interacting with nitric oxide (NO). Research also shows that acute administration of metabolic substrates, like oxygen and glucose, can enhance aspects of cognitive performance in young, healthy humans. The aim of this investigation was to determine if the consumption of resveratrol could modulate cerebral blood flow and if this in turn could influence cognitive performance by increasing access to blood borne metabolic fuel. Results showed that compared to placebo, after consuming 500mg pure trans-resveratrol, levels of total haemoglobin were significantly higher in the frontal cortex of young, healthy participants during cognitive task completion. Cognitive performance was not effected.

Condition	Intervention
Cognitive and Cerebral Blood Flow Effects of Resveratrol	Dietary Supplement: Trans- resveratrol Other: Placebo (silica)

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Investigator, Outcomes Assessor) Primary Purpose: Basic Science
Official Title:	Effects of Resveratrol on Cerebral Blood Flow Parameters and Cognitive Performance in Humans: a Double-blind, Placebo-controlled, Crossover Investigation

Resource links provided by NLM:

Drug Information available for: Resveratrol Silicon dioxide

U.S. FDA Resources

Further study details as provided by Northumbria University:

Primary Outcome Measures:

Modulation of Levels of Total Haemoglobin [ Time Frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) ] [ Designated as safety issue: No ]
This outcome measure provides the change from baseline values (in µmol/L) of total levels of haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).
Modulation of Deoxygenated Levels of Haemoglobin [ Time Frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) ] [ Designated as safety issue: No ]
This outcome measure provides the change from baseline values (in µmol/L) of levels of deoxygenated haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).

Secondary Outcome Measures:

Number of Participants With Significant Modulation of Cognitive Performance [ Time Frame: 46-81 mins post dose ] [ Designated as safety issue: No ]
This outcome measure assessed any significant modulation of cognitive task performance during the 46-81 min post dose period. The cognitive tasks utilized were cognitively demanding computer based, numerical tasks which assessed working memory. Significant modulation is defined as significant difference between baseline and post-dose task performance.

Enrollment:	24
Study Start Date:	June 2008
Study Completion Date:	March 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Resveratrol 250mg	Dietary Supplement: Trans- resveratrol All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner. Other Name: Transmax from Biotivia. Other: Placebo (silica) All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner. Other Name: Pharmaceutical grade silica
Experimental: Resveratrol 500mg	Dietary Supplement: Trans- resveratrol All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner. Other Name: Transmax from Biotivia. Other: Placebo (silica) All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner. Other Name: Pharmaceutical grade silica
Placebo Comparator: Placebo	Dietary Supplement: Trans- resveratrol All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner. Other Name: Transmax from Biotivia. Other: Placebo (silica) All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner. Other Name: Pharmaceutical grade silica

Eligibility

Ages Eligible for Study:	18 Years to 35 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Male/female,
Healthy
Age 18-35 years old
Non smoker
Proficient in English
Not taking any herbal or prescription medications
Not pregnant
Does not drink more than 6 cups of coffee per day

Exclusion Criteria:

Suffered a head injury, neurological disorder or neuro-developmental disorder
Food allergies/intolerances

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01010009

Locations

United Kingdom
Northumbria University
Newcastle upon Tyne, United Kingdom, NE1 8ST

Sponsors and Collaborators

Northumbria University

Investigators

Study Director:

Crystal Haskell

Northumbria University

More Information

No publications provided

Responsible Party:	Emma Wightman, Northumbria University
ClinicalTrials.gov Identifier:	NCT01010009 History of Changes
Other Study ID Numbers:	22P2
Study First Received:	November 6, 2009
Results First Received:	June 26, 2010
Last Updated:	May 17, 2012
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by Northumbria University:

resveratrol
cerebral blood flow
NIRS
cognitive performance

Additional relevant MeSH terms:

Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents

Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Hematologic Agents
Antimutagenic Agents
Anticarcinogenic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 16, 2013